Allogenic adipose-derived mesenchymal stem cell therapy - Regeneus ltd

Drug Profile

Allogenic adipose-derived mesenchymal stem cell therapy - Regeneus ltd

Alternative Names: PRG; Progenza

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regeneus ltd
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 13 Mar 2018 Adverse events and efficacy data from a phase I STEP trial in Osteoarthritis released by Regeneus
  • 24 Mar 2017 Regeneus completes the phase I STEP trial in Osteoarthritis in Australia (Intra-articular) (ACTRN12615000439549)
  • 29 Dec 2016 Progenza licensed to AGC Asahi Glass in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top